SHOX (short stature homeobox-containing gene) encodes a transcription factor implicated in skeletal development. SHOX haploinsufficiency has been demonstrated in Leri -Weill dyschondrosteosis (LWD), a skeletal dysplasia associated with disproportionate short stature, as well as in a variable proportion of cases with idiopathic short stature (ISS). In order to gain insight into the SHOX signalling pathways, we performed a yeast two-hybrid screen to identify SHOX-interacting proteins. Two transcription factors, SOX5 and SOX6, were identified. Co-immunoprecipitation assays confirmed the existence of the SHOX -SOX5 and SHOX -SOX6 interactions in human cells, whereas immunohistochemical studies demonstrated the coexpression of these proteins in 18-and 32-week human fetal growth plates. The SHOX homeodomain and the SOX6 HMG domain were shown to be implicated in the SHOX -SOX6 interaction. Moreover, different SHOX missense mutations, identified in LWD and ISS patients, disrupted this interaction. The physiological importance of these interactions was investigated by studying the effect of SHOX on a transcriptional target of the SOX trio, Agc1, which encodes one of the main components of cartilage, aggrecan. Our results show that SHOX cooperates with SOX5/SOX6 and SOX9 in the activation of the upstream Agc1 enhancer and that SHOX mutations affect this activation. In conclusion, we have identified SOX5 and SOX6 as the first two SHOX-interacting proteins and have shown that this interaction regulates aggrecan expression, an essential factor in chondrogenesis and skeletal development.
INTRODUCTION
SHOX (short stature homeobox-containing gene) is located in the pseudoautosomal region 1 (PAR1) of the X and Y chromosomes (1, 2) . Mutations and deletions of SHOX and/or the downstream PAR1 containing SHOX enhancer elements have been reported in Leri-Weill dyschondrosteosis (LWD, MIM 127300), Langer mesomelic dysplasia (LMD, MIM * To whom correspondence should be addressed at: Instituto de Genética Médica y Molecular (INGEMM), Hospital Universitario La Paz, P8 Castellana 261, 28046 Madrid, Spain. Tel: +34 917277469; Fax: +34 912071040; Email: kheath.hulp@salud.madrid.org 249700) and idiopathic short stature (ISS, MIM 300582) (1,3 -8) . LWD is a skeletal dysplasia associated with disproportionate short stature due to mesomelic shortening of the limbs, and the characteristic abnormality of the forearms known as Madelung deformity: bowing of the radius and dorsal dislocation of the distal ulna. Alterations in SHOX or its enhancers (SHOX/ PAR1) have been identified in 60% of LWD individuals (9 -11) . LMD is due to homozygous or compound heterozygous SHOX/PAR1 alterations resulting in severely disproportionate short stature with marked mesomelic and rhizomelic limb shortening. SHOX/PAR1 alterations have also been found in 5% of ISS cases (11) , a condition defined as a height below 22 SDS in the absence of known specific causative disorders (12) . Together, the estimated prevalence of SHOX haploinsufficiency is 1 in 1000 individuals.
However, there is some evidence suggesting genetic heterogeneity in LWD: first, the molecular defect in 40% of LWD cases remains unknown (9 -11) , and secondly, the PAR1 has been excluded by linkage analysis as the causative region in a multigenerational LWD family (S. Benito-Sanz et al., unpublished data).
Two SHOX isoforms exist, SHOXa and SHOXb (1), both contain a homeodomain, but only SHOXa (SHOX) acts as a transcriptional activator in osteogenic cells via its transactivation domain, the OAR (otp, aristaless and rax), which is absent in SHOXb. Recently, NPPB, which encodes brain natriuretic peptide, an important regulator of endochondral ossification, has been identified as the first transcriptional target of SHOX (13) .
There is robust evidence in the literature for the implication of SHOX in chondrogenesis: (i) SHOX is expressed in the middle part of the developing human limbs during chondrogenesis, from the condensing mesenchyme forming the precartilaginous structure of the bone to the start of ossification (14) ; (ii) Shox overexpression promoted chondrogenesis in chicken micromass cultures, observed by the increased expression of Col2a1 and Agc1, which encode the cartilage matrix components collagen type II and aggrecan, respectively, and by the enhanced Alcian blue staining (15) ; and (iii) SHOX overexpression induces growth arrest and apoptosis in human primary chondrocytes (16) . Despite these recent advances, the precise role of SHOX in bone development still remains elusive.
In order to identify the signalling pathways in which SHOX intervenes and to discover potential gene candidates involved in the pathogenesis of LWD, a yeast two-hybrid screen of a whole mouse embryo cDNA library was performed using SHOX as bait. Among the large number of potential SHOX interactors, we identified two transcription factors, Sox5 and Sox6, which together with Sox9 form the Sox trio, the master complex of chondrogenesis (17) . We confirmed that the human SOX5 and SOX6 homologues also interact with SHOX and demonstrated that SHOX missense mutations impair the SHOX -SOX6 interaction. Interestingly, we also showed that SHOX cooperates with SOX5/SOX6 and SOX9 in the activation of the Agc1 enhancer and that SHOX mutations impair this activation. In summary, we have identified and characterized SOX5 and SOX6 as the first two SHOX-interacting proteins and defined a function for this protein complex during chondrogenesis.
RESULTS

Identification of two SHOX-interacting proteins
In order to identify proteins which interact with SHOX, a whole mouse embryo 9.5 -10.5 dpc cDNA library was screened in a yeast two-hybrid system with full-length SHOX cDNA as bait. A total of 36 positive colonies were identified. The plasmids containing the cDNA sequence of the putative SHOX interaction partners were extracted from the cotransformed PJ69-4A yeast cells, transformed into Escherichia coli cultures and sequenced. BLAST searches of the sequences of all positive colonies were performed against EMBL (www.ebi.ac.uk/embl) and SPTR (www.unip rot.org) databases and Unigene clusters (www.ncbi.nlm.nih. gov/unigene). Twelve of the positive clones (33%) were excluded from further analysis because they lacked biological sense (i.e. the cDNA sequence was out of frame or corresponded to untranslated regions). The remaining 24 positive clones (67%) encoded full-length, or almost full-length, in-frame cDNA inserts. Three of the 24 positive cDNAs (12.5%) corresponded to Sox5 and Sox6, two transcription factors involved in chondrogenesis (18, 19) . The detected interactions were first validated by means of a bait/prey switch, placing the full-length SHOX cDNA in the pVP16 vector and the Sox5 and Sox6 cDNA fragments into the pGBDU vector (data not shown). The interactions between the respective proteins were confirmed using SOX5 and SOX6, the human homologues of Sox5 and Sox6. For this purpose, we cloned the human full-length homologue SOX5 and SOX6 cDNAs into the pGBT9 vector and cotransformed them into the yeast cells with pACT2:SHOX. SHOX homodimerization was used as a positive control (20) . Both human SOX5 and SOX6 interacted with SHOX ( Fig. 1) .
Confirmation of the SHOX-SOX5 and SHOX-SOX6 interactions
Confirmation of the identified interactions was subsequently performed using coimmunoprecipitation in human cells and immunohistochemical analysis in human fetal growth plates. . SHOX interacts with SOX5 and SOX6 in the yeast two-hybrid system. The S. cerevisiae strain Y187 was cotransformed with the pGBT9 and pACT2 vectors. Yeast cells were selected on SD growth medium lacking Trp and Leu. Interactions were determined by using a b-galactosidase liquid assay with CRPG as substrate. Protein interaction percentages were obtained by normalizing the b-galactosidase units of the different construct combinations to that of SHOX homodimerization (black bar). Empty vectors were employed as negative controls. All values represent the mean and the standard deviation of five independent transformation experiments, each performed in triplicate.
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Human Molecular Genetics, 2011, Vol. 20, No. 8 SHOX interacts with SOX5 and SOX6 in human cells. Nuclear lysates of human HEK293 cells overexpressing the proteins of interest were immunoprecipitated with anti-FLAG-agarose beads and analysed by western blot using SHOX, SOX5 and SOX6 antibodies. In agreement with the yeast two-hybrid experiments, SOX5 and SOX6 coprecipitated with SHOX ( Fig. 2) , confirming the interaction between these proteins in human cells.
SHOX, SOX5 and SOX6 are coexpressed in 18-and 32-week human fetal growth plates. By immunohistochemistry, we observed the expression of all three proteins in the reserve, proliferative and hypertrophic zones of both gestational ages (Fig. 3 , Supplementary material, Figs S1 and S2). Since SOX5 and SOX6 cooperate with SOX9 during chondrogenesis (17) and Sox9 is needed for Sox5 and Sox6 expression (21), we analysed and subsequently confirmed that SOX9 is coexpressed with SHOX, SOX5 and SOX6 in the same zones of both growth plates (Fig. 3 , Supplementary material, Figs S1 and S2). These findings provide the first evidence of coexpression of SHOX, SOX5, SOX6 and SOX9 in the human fetal growth plate.
SHOX domains involved in the interaction with SOX6
Since Sox5 and Sox6 have been shown to be highly homologous and functionally redundant (18, 19) , and in yeast, the SHOX -SOX6 interaction was stronger than SHOX -SOX5, we characterized the domains implicated in the SHOX -SOX5/SOX6 interaction using SOX6 and a series of SHOX domain constructs. Four SHOX constructs, SHOX(1 -178), SHOX(1 -211), SHOX(117 -274) and SHOX(117 -292), all of which include the homeodomain, were shown to interact with SOX6 (Fig. 4) , thus suggesting that this domain is implicated in the SHOX-SOX6 interaction. However, the SHOX construct containing only the homeodomain, SHOX(117 -178), did not interact with SOX6 (Fig. 4) . Thus, either the N-and/or the C-terminal region may participate in the SHOX -SOX6 interaction or may confer structural stability in yeast to the interacting domain, the homeodomain.
SHOX mutants impair the SHOX-SOX6 interaction
To further characterize the interaction between SOX6 and SHOX, we expressed 10 SHOX missense mutations (Fig. 5A) in the pACT2 vector and tested their capacity to bind SOX6 in cotransformation experiments with wild-type SOX6 in the pGBT9 vector. Seven of these mutations, located in the N-terminus or the homeodomain, have been previously reported in patients with LWD or ISS ( Fig. 5A ; www. hd-lovd.uni-hd.de/). Since no missense mutation in the C-terminal region of SHOX had been described at the time of the assay design, we generated three artificially SHOX mutant proteins, R195P, A233E and D278A, which substitute highly conserved amino acids in the C-terminal region with structurally different residues. Eight missense mutations have since been described in the SHOX C-terminal region (www.hd-lovd.uni-hd.de/), two affecting residues that we targeted: R195N and A233V. All analysed mutant SHOX proteins which failed to bind SOX6 (L132V, R168W, A170P and R173C) harboured mutations located in the homeodomain region ( Fig. 5A and B) , thus confirming that the SHOX homeodomain is directly involved in the interaction with SOX6. Interestingly, the homeodomain mutation R153L did not impair the ability of SHOX to bind SOX6 ( Fig. 5A and B). The N-terminal mutation K116E caused a 60% reduction in the interaction with SOX6 (Fig. 5B ), suggesting that this residue, close to the homeodomain boundary, may either participate in the interaction or confer structural stability to the homeodomain. The three mutations located in the C-terminal region caused a milder reduction (25 -40%) in SHOX interaction with SOX6 (Fig. 5B ). In conclusion, our results indicate that mutations in the SHOX homeodomain, except R153L, affect the interaction with SOX6, confirming that this domain is critical for the interaction with SOX6.
SOX6 domains involved in the interaction with SHOX
To characterize the SOX6 domain involved in the interaction with SHOX, we generated a series of SOX6 cDNA deletion constructs in the pGBT9 vector and used them in cotransformation experiments with the wild-type SHOX in the pACT2 vector (Fig. 6A ). Two constructs, SOX6(263-787) and SOX6(479-787), both of which share the DNAbinding HMG domain, interacted with SHOX ( Fig. 6 ), indicating that this domain is directly involved in the interaction with SHOX. The construct containing the HMG domain, SOX6(479-787), interacted with SHOX more weakly than SOX6(263-787), suggesting that the second coiled-coil may also participate in the interaction, although it is unable to interact alone, or, alternatively, it may confer structural stability in yeast to the true interacting domain, the HMG domain. SHOX cooperates with SOX5/SOX6 and SOX9 in the activation of the Agc1 enhancer
In order to assess the physiological significance of the SHOX -SOX5 and SHOX-SOX6 interactions, we investigated their capacity to transactivate SOX trio target genes. The SOX trio has been shown to induce aggrecan expression, a marker of chondrocyte differentiation, by activating the Agc1 enhancer (22) . It has also been observed that Shox overexpression increased Agc1 expression in chicken micromass cultures (15) , thus suggesting that Shox is involved in the expression of Agc1.
To examine whether SHOX participates in the expression of Agc1, we performed a luciferase assay in U2OS cells. The osteogenic cells were cotransfected with different combinations of SHOX, SOX5/SOX6 and SOX9 expression plasmids and a luciferase reporter plasmid containing four tandem copies of the far-upstream Agc1 enhancer followed by the Col2a1 289 to +6 promoter (22) (kind gift of V. Lefebvre). Coexpression of SHOX with the three SOX proteins was not undertaken as no significant increase in aggrecan expression was previously observed compared with the coexpression of SOX5 or SOX6 with SOX9 (22) . Western blot analysis were performed to ensure the expression of the various proteins (data not shown). As described previously, SOX9 overexpression was able to induce the Agc1 enhancer (22) , and coexpression of SOX5 or SOX6 and SOX9 highly activated this enhancer (Fig. 7) . In contrast, the coexpression of SHOX with SOX5/SOX6 was unable to induce the Agc1 enhancer ( Fig. 7 ) and the addition of SHOX did not improve the transcriptional capacity of SOX9. Interestingly, overexpression of SHOX, SOX5/SOX6 and SOX9 increased the activation of the Agc1 enhancer ( Fig. 7A and B) , from which we conclude that SHOX cooperates with SOX5/SOX6 and SOX9 in the activation of the upstream Agc1 enhancer.
Subsequently, we studied whether SHOX mutants impaired the Agc1 enhancer activation. The SHOX Q211X mutant, previously denominated as SHOX(1 -211) (Fig. 4) , failed to activate the Agc1 enhancer ( Fig. 8A and B) , whereas L132V and R168W mutants showed a decreased ability to activate the enhancer ( Fig. 8A and B) . Once again, the SHOX R153L mutant behaved differently when compared with the other homeodomain mutants, retaining its ability to activate the Agc1 enhancer at levels similar to wild-type SHOX (Fig. 8 ).
SOX5 and SOX6 mutation screening in LWD individuals without SHOX/PAR1 alterations In order to explore the involvement of SOX5 and SOX6 in the molecular aetiology of LWD, we undertook mutation screening of the coding regions and intron/exon boundaries of SOX5 and SOX6 in 37 individuals with definite or possible LWD without a known molecular defect. No SOX5 or SOX6 point mutations, small deletions or insertions were identified in this cohort. The probability of complete or intragenic SOX5 deletions was reduced in 36 patients, through the observation of two alleles for a microsatellite marker located in the 5 ′ -flanking region of SOX5, and/or nine intragenic singlenucleotide polymorphisms (SNPs): c.231 + 53 C . A, Figure 3 . SHOX is coexpressed with SOX5, SOX6 and SOX9 in the human fetal growth plate. Immunohistochemistry performed on 18-and 32-week human fetal tibia growth plates. DAB immunostaining at 20× magnification against SHOX, SOX5, SOX6 and SOX9 antibodies in 18-and 32-week fetal growth plates. Specific staining can be observed in the reserve, proliferative and hypertrophic zones of the growth plate for the four proteins.
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Human Molecular Genetics, 2011, Vol. 20, No. 8 rs7980561, rs11047075, c.771 + 118 G . A, rs11047034, rs1479452, rs7485662, rs76722400 and rs4636755. The probability of the existence of complete or partial SOX6 deletions was reduced in 32 patients by a self-designed MLPA (multiplex ligation-dependent probe amplification) assay and/or by the presence in heterozygosity of at least one of the observed intragenic SNPs: rs4617548, c.1733-41 C . T and c.2183 + 7 A . G.
DISCUSSION
In this work, we identified SOX5 and SOX6 as SHOX-interacting proteins using a yeast two-hybrid assay and confirmed the findings by coimmunoprecipitation in human cells and immunohistochemistry in human fetal growth plates. The domains involved in the SHOX -SOX6 interaction were characterized using protein fragments and a series of SHOX mutants. These experiments revealed that the SHOX homeodomain interacts with the HMG domain of SOX6.
Our data are therefore consistent with previous reports, where the Sox HMG domain has been shown to interact with the DNA-binding domain of several transcription factors (23) . However, we cannot discard that the N-and C-terminal regions of SHOX and the SOX6 second coiledcoil are also implicated in the SHOX -SOX6 interaction, at least conferring structural stability to the interacting domains. Four of the five analysed SHOX homeodomain mutants failed to interact with SOX6, whereas, interestingly, the R153L mutation retained its binding ability. This is the only analysed mutation in helix II of the homeodomain, suggesting that helix II does not participate in the interaction with SOX6 or that this change does not affect the interaction with SOX6. The SHOX mutants located outside of the homeodomain showed a variable reduction in their interaction ability, suggesting that the conformation of the SHOX protein may be important for the interaction with SOX5 and SOX6.
Both Sox5 and Sox6 are essential for chondrogenesis (24) , cooperating with Sox9 to form the Sox trio, which has been shown to directly activate three genes encoding extracellular matrix proteins: Col2a1 (25), Agc1 (22) and Comp (26). However, it has been suggested that additional unknown transcription factors work together with the Sox trio to promote chondrocyte overt differentiation (17) . Little is known about the function and signalling pathways in which SHOX intervenes but it has been observed that Shox overexpression promotes chondrogenesis in chicken micromass cultures, shown by increased Col2a1 and Agc1 expression (15) . These observations prompted us to study the role of SHOX-SOX5 and SHOX -SOX6 interactions in the regulation of the SOX trio transcriptional target, Agc1. SHOX was shown to cooperate with SOX5/SOX6 and SOX9, significantly activating the transcriptional activity of the Agc1 enhancer.
This cooperation was impaired by SHOX mutants which altered the transcriptional activity of the Agc1 enhancer. SHOX mutants that were unable to interact with SOX6, such as the homeodomain mutants L132V and R168W, also altered the transcriptional activity of the Agc1 enhancer. In contrast, the R153L homeodomain mutant retained its ability to bind to SOX6 and activate the Agc1 enhancer, but failed to transactivate NPPB (13), thus suggesting that the molecular mechanism by which SHOX transactivates NPPB and Agc1 is different. These results suggest that the SHOX-SOX6 interaction is important for the activation of the Agc1 enhancer. However, since the L132V and R168W mutants cannot dimerize to SHOX or bind DNA, and the R153L mutant conserves these abilities (27) , we cannot exclude the possibility that the L132V and R168W mutants failed to activate the Agc1 enhancer because they lost their capacity to transactivate. The SHOX mutant Q211X, which lacks the OAR domain, conserved its interaction capacity with SOX6 (50%), but failed to activate the Agc1 enhancer, thus indicating that the transactivation domain of SHOX is necessary for the activation of the Agc1 enhancer. Despite these molecular findings, the phenotype observed in individuals with these four mutants is indifferent, presenting predominantly as LWD but in a few cases as ISS.
We searched for the presence of SHOX-binding sequences, i.e. P2-P6 elements, in the Agc1 enhancer. No P2 -P6 element sequence with .75% identity to the consensus sequence of other homeodomain proteins was detected (Jaspar database, www.jaspar.genereg.net/). However, no perfect binding site was found in the SHOX-binding region of the NPPB promoter (13) , suggesting that SHOX may bind, in vivo, to an imperfect P element in the Agc1 enhancer. In support of this hypothesis, we excluded the possibility that SHOX acts as a connecting protein between SOX5/SOX6 and SOX9 by coimmunoprecipitation (Supplementary material, Fig. S3 ). Thus, we propose that the SHOX homeodomain interacts with the SOX5/SOX6 HMG domain, whereas SOX5/SOX6 and SOX9 are bound to the Agc1 enhancer and SHOX may or may not be bound to this regulatory region.
We also showed that SHOX, SOX5, SOX6 and SOX9 are coexpressed in resting, proliferative and hypertrophic chondrocytes of the 18-and 32-week human fetal growth plates. Our data are not concordant with the Sox5, Sox6 and Sox9 mRNA expression data reported in mouse embryos, where Sox5, Sox6 and Sox9 were turned off upon chondrocyte prehypertrophy (25) . However, immunohistochemical staining of tibia growth plate sections of an E16 mouse fetus (Supplementary material, Fig. S4 ) and previously described immunohistochemistry assays performed in E17.5 mouse fetal growth plates (28) confirmed that Sox5, Sox6 and Sox9 proteins are also expressed in mouse hypertrophic chondrocytes.
Both models of three null allele Sox5 and Sox6 knockout mice had short and bent forelimbs (19) , showing some similarities to the phenotype observed in LWD, thus suggesting that Sox5 and Sox6 could be alternative genes implicated in this aetiology. However, mutation screening of SOX5 and SOX6 coding regions did not detect any mutation in the studied cohort. Analysis of a larger cohort and mutation screening of the SOX5 and SOX6 regulatory regions are necessary to properly assess their involvement in this pathology.
In conclusion, our work has identified the chondrogenic transcription factors SOX5 and SOX6 as the two first SHOXinteracting proteins and has shown that SHOX cooperates with SOX5/SOX6 and SOX9 in the activation of the Agc1 enhancer that regulates the expression of aggrecan, an essential extracellular matrix component of cartilage. Our work provides an insight into the function of SHOX and improves our knowledge about chondrogenesis and skeletal development.
MATERIALS AND METHODS
Generation of recombinant constructs
The full-length cDNA of SHOX (NM_000451), SOX5 (NM_152989), SOX6 [corresponding to a splicing variant highly expressed in chondrocytes and lacking exon 9 but including exon 14a, using the exonic nomenclature described by Cohen-Barak et al. (29) , and kindly donated by Dr T. Ikeda] and SOX9 (NM_000346) were amplified by polymerase chain reaction (PCR) and cloned into the pCR2.1 vector (Invitrogen) using appropriate oligonucleotides (Table 1) and TA cloning (Invitrogen), according to the manufacturer's instructions. Full-length SHOX cDNA was first subcloned into the pEG202 expression vector (Clontech) and then shuttled into the yeast expression vector pGBDU (kindly donated by Dr Stan Hollenberg, Vollum Institute, OR, USA). SHOX cDNA was also subcloned into the yeast expression vector pACT2 (Clontech) and the mammalian expression vectors pcDNA3-FLAG and pcDNA3-HA (Invitrogen). SOX5 and SOX6 cDNAs were subcloned into the yeast expression vector pGBT9 (Clontech) and into the mammalian expression vector pcDNA3-HA (Invitrogen), as was SOX9 cDNA. SOX6 cDNA was also subcloned into the mammalian expression vector pcDNA3-FLAG (Invitrogen). Various SHOX and SOX6 fragments were also inserted into the TA cloning vector using appropriate oligonucleotides (Table 1) and subsequently subcloned into the vectors pACT2 and pGBT9, respectively. The introduction of the SHOX missense mutations and the generation of some SHOX and SOX6 fragments were performed using the QuickChange Site-Directed Mutagenesis Kit (Stratagene), appropriate mutagenic oligonucleotides (Table 2 ) and different plasmids as templates. All expression constructs were sequenced to exclude the presence of undesired mutations resulting from PCR amplification. The previously reported Agc1 enhancer plasmid (4XA1)pCol2Luc (22) was kindly donated by Dr Veronique Lefebvre. This consisted of four tandem repeats of a 359 bp cartilage-specific enhancer, which starts 9477 bp upstream the Agc1 mouse transcription start site (4XA1), followed by 289 to +6 Col2a1 promoter (pCol2) driving the expression of the firefly luciferase gene (Luc).
Yeast two-hybrid screens
We used the pGBDU:SHOX full length as bait, a whole mouse embryo 9.5-10.5 dpc random primed cDNA library in pVP16 (kindly donated by Dr Stan Hollenberg, Vollum Institute, OR, USA) and the Saccharomyces cerevisiae strain PJ69-4A. In brief, yeast cells containing the bait plasmid were transformed with the cDNA library using the LiAc/ssDNA/PEG-heat shock protocol following the manufacturer's instructions (Matchmaker Yeast Protocol Handbook, Clontech). We screened 250 000 transformants for growth in synthetic dropout (SD) interacting media lacking leucine, uracyl and histidine amino acids (Clontech) and supplemented with 2 mM 3-aminotriazole (3AT, Sigma). The plates were incubated at 308C for 3 -5 days. Colonies (n ¼ 51) were replated in duplicate onto SD media lacking leucine, uracyl, adenine and histidine (Clontech) and supplemented with 3.5 mM 3AT. Four of the 51 colonies picked showed no growth on this medium and were excluded from further analysis. b-Galactosidase assays on duplicates of these cotransformations excluded an additional four colonies as they were negative for this assay. Overnight cultures of the 43 remaining colonies were grown from the duplicate plate. The insert from the library plasmid was amplified by PCR. Single PCR products obtained for 36 of these samples were sequenced using oligonucleotides surrounding the cloning site. In order to exclude the spurious activation of the system, the pGBDU:SHOX bait was transformed with PVP16 empty vector into PJ69-4A yeast cells, and cells were replated in duplicate onto SD interacting media (SD media lacking leucine and uracyl; SD media lacking leucine, uracyl and adenine; SD media lacking leucine, uracyl and histidine and supplemented with 3.5 mM 3AT). No autoactivation was detected.
Yeast two-hybrid cotransformation and b-galactosidase liquid assay
Cotransformations of the human SHOX, SOX5 and SOX6 constructs into S. cerevisiae strain Y187 were performed using the LiAc/ssDNA/PEG-heat shock protocol. Transformed cells The incorporated enzymes sites are indicated with lower case letters. 
Coimmunoprecipitation
HEK293 cells were grown in Dulbecco's modified Eagle's medium (Invitrogen), supplemented with 10% fetal bovine serum (Gibco) and 1% penicillin/streptomycin (Invitrogen). Twenty-four hours before transfection, cells were seeded in a 10 cm plate at a density of 3 × 10 6 cells. Medium was changed prior to transfection. Cells were then cotransfected with 10 mg of each plasmid using FUGENE6 transfection reagent (Roche) at a FUGENE6:DNA ratio of 2.5:2. Twentyfour hours post-transfection, cells were lysed using the reagents from the Nuclear Complex co-IP kit (Active Motif) and following the manufacturer's instructions. Nuclear extracts were immunoprecipitated with 20 ml of anti-FLAG M2-agarose beads (Sigma-Aldrich) using reagents of the Nuclear Complex co-IP kit (Active Motif) and following the manufacturer's instructions.
Western blot analysis
Proteins from cell extracts and immunoprecipitation samples were separated by sodium dodecyl sulphate -polyacrylamide gel electrophoresis and transferred to nitrocellulose membrane (BioRad). Membranes were blocked overnight at 48C in TN buffer (Tris 50 mM, pH ¼ 8, NaCl 150 mM, Sigma-Aldrich) with 0.05% Tween 20 (Sigma-Aldrich), 5% non-fat dry milk and 3% bovine serum albumin (Sigma-Aldrich). Blots were then incubated for 2 h at room temperature with various antibodies: rabbit polyclonal anti-SHOX (20) at a dilution of 1:3000, rabbit polyclonal anti-SOX5 (Ab26041, Abcam) at a dilution of 1:2000, rabbit polyclonal anti-SOX6 
Immunohistochemistry
Human tibia growth plate sections were obtained from two spontaneously aborted normal fetuses of 18 and 32 weeks, after obtaining informed consent. Paraffin sections of growth plates were deparaffinized and rehydrated to water. Exogenous peroxidase was quenched with 0.3% H 2 O 2 in methanol, and the non-specific antibody-binding sites were blocked using 10% normal goat serum (Vector Laboratories). The sections were incubated at 48C overnight with the antibodies, described previously, at the following dilutions: SHOX (1:50), SOX5 (1:50), SOX6 (1:25) and SOX9 (1:50). The biotin/avidinhorseradish peroxidase system (ABC Universal kit, Vector Laboratories) was used to detect antibody binding, and diaminobenzidine (DAB; Vector Laboratories) was used to visualize the results. Cells were then stained with haematoxylin (Sigma-Aldrich) for 2 min and finally mounted with Depex (BDH). Negative controls were performed by (i) replacing the primary antibody with phosphate-buffered saline, (ii) using a rabbit polyclonal IgG isotype control (Ab27472, Abcam) at a dilution of 1:50 or (iii) using preimmune serum from the rabbit immunized with the SHOX peptide, at a dilution of 1:1000. Sections of a normal adult colon were also used as negative control tissue with the SHOX, SOX5, SOX6 and SOX9 antibodies. Sections were examined using a BX41 microscope (Olympus), and photos were taken using a DP20 digital camera (Olympus) with CellA software (Olympus).
Luciferase assay
U2OS cells were seeded in 12-well plates at a density of 160 000 cells/well. Reporter constructs were cotransfected with expression plasmids using FUGENE6 transfection reagent (Roche) according to the manufacturer's instructions and with a 3:2 FUGENE:DNA ratio. DNA included 300 ng of PRL-TK control plasmid, 1500 ng of (4XA1)pCol2Luc reporter plasmid (control and reporter plasmids were transfected in a 1:5 ratio) and 250 ng of SHOX, SOX5, SOX6 or SOX9 expression plasmids (pcDNA3-FLAG or pcDNA3-HA vectors). Empty expression plasmid was added, whenever necessary, to normalize DNA concentrations. Each plasmid combination was transfected in three wells. Twenty-four hours later, cells were lysed and the reporter activity was measured in triplicate using the Dual luciferase reporter assay system (Promega) according to the manufacturer's instructions. Each sample was normalized, first, with respect to the renilla luciferase activity, and then secondly, to that transfected only with the reporter plasmid. Statistical analyses were undertaken with SPSS v15.0 for Windows. We employed one-factor analysis of variance (ANOVA) with the Bonferroni post hoc test for analysing the results of luciferase assay.
SOX5 and SOX6 mutation screening
Patients. Ethical approval was obtained from the respective institutions. The cohort consisted of 37 probands with LWD or suspected LWD. All participants provided informed consent for the performed studies. Clinical details were obtained for all patients recruited into the study. Whenever possible, these included birth details, anthropometric measurement, actual height and height standard deviation scores (SDSs) according to the national standards (30) , physical examination of extremities and X-rays of the lower arm. Family histories were also documented, including parental heights. In all cases, the presence of SHOX/PAR1 alterations had been excluded previously (5, 9) . Peripheral blood was drawn from probands for DNA extraction. Genomic DNA was isolated by the salt precipitation method (31) . The screening of point mutations, small deletions and insertions in the coding sequences and intron/exon boundaries of SOX5 (ENST00000451604) and SOX6 (ENST00000 316399) was performed by denaturing high-performance liquid chromatography (dHPLC, Transgenomic Wave 3500HT), and subsequent sequencing of any identified heteroduplex using the BigDye Terminator V3.1 kit (Applied Biosystems). PCR conditions were as described previously (5). Primer sequences, amplicon sizes, PCR annealing temperatures and dHPLC conditions for SOX5 and SOX6 are available in Tables 3 and 4, respectively. SOX5 deletion analysis was undertaken through the detection of heterozygosity of a (GA)n dinucleotide repeat marker located 53 kb upstream of SOX5 exon 1 and by the detection of heterozygosity of SNPs in the SOX5 amplicons. Analysis of the patients for the SOX5 microsatellite marker was undertaken using the following oligonucleotides: 5 ′ -CCGCTGCT GGAAGTG-3 ′ and 5 ′ -CCACCTATGATCGTCTCCAA-3 ′ . PCR conditions were as previously described (5) and the amplicon annealing temperature was 558C. Amplification products were separated using an ABI 3130 Sequencer.
SOX6 large deletions and duplications were studied in our cohort by observing heterozygosity of SNPs in the SOX6 amplicons and by using a SOX6 self-designed MLPA assay. This consisted of 11 SOX6 probes and three control fragments (Table 5) . MLPA reactions were carried out using an EK1 SALSA MLPA Kit (MRC-Holland, Amsterdam, The Netherlands) according to the manufacturer's protocol. The ratios of the test's peak areas versus those of the control samples were determined using an Excel data sheet. Normal peaks were classified as showing a ratio of 0.65 -1.35, whereas deletions and duplications were classified as having a ratio ,0.65 or .1.35, respectively. 
